Sign Up Today and Learn More About Abnormal AI Stock
Invest in or calculate the value of your shares in Abnormal AI or other pre-IPO companies through EquityZen's platform.
Abnormal AI Stock (ABSE)
Abnormal AI is the leading AI-native human behavior security platform.
About Abnormal AI Stock
Founded
2018
Headquarters
Las Vegas, NV, US
Industries
Software, Data and Analytics, Science and Engineering
Abnormal AI is an AI-native cybersecurity platform designed to identify abnormal human behavior and automate responses to protect against phishing, social engineering, and account takeovers.
Abnormal AI Press Mentions
Stay in the know about the latest news on Abnormal AI
AI executive pleads guilty to assaulting musicians in pub, keeps job
smh • May 05, 2026
Abnormal AI Expands Leadership Team to Advance Behavioral AI Platform
businesswire • Apr 30, 2026
Abnormal AI 2026 Attack Landscape Report: Threat Actors Move Beyond Technical Exploits to Target Human Behavior and Trusted Relationships
morningstar • Apr 23, 2026
Abnormal AI 2026 Attack Landscape Report: Threat Actors Move Beyond Technical Exploits to Target Human Behavior and Trusted Relationships
businesswire • Apr 23, 2026
Career CISO Patricia Titus Brings Depth of Security and Protection Expertise to BlackCloak Advisory Board
prweb • Mar 10, 2026
Investors in Abnormal AI
Discover investors in Abnormal AI stock and explore their portfolio companies
Abnormal AI Management
Leadership team at Abnormal AI
Founder & CEO
Evan Reiser
President
Michael DeCesare
Join now and verify your accreditation status to gain access to:
- Abnormal AI Current Valuation
- Abnormal AI Stock Price
- Abnormal AI Management
- Available deals in Abnormal AI and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Abnormal AI Cap Table and Funding History by Share Class and Liquidity Preferences
- Abnormal AI Revenue and Financials
- Abnormal AI Highlights
- Abnormal AI Business Model
- Abnormal AI Risk Factors
- Abnormal AI Research Report from SACRA Research
Trading Abnormal AI Stock
How to invest in Abnormal AI stock?
Accredited investors can buy pre-IPO stock in companies like Abnormal AI through EquityZen funds. These investments are made available by existing Abnormal AI shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Abnormal AI stock?
Shareholders can sell their Abnormal AI stock through EquityZen's private company marketplace. EquityZen's network includes over 450K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
